FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	STATEMENT OF C
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	Filed pursuant to S

HANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* SISKOWSKI GARY A (Last) (First) (Middle)							Suer Name and Ticker or Trading Symbol NABI BIOPHARMACEUTICALS [NABI] Date of Earliest Transaction (Month/Day/Year)									all applicable) Director Officer (give title below)		p Person(s) to Issuer 10% Owner Other (specify below)		Owner (specify
C/O NABI BIOPHARMACEUTICALS 5800 PARK OF COMMERCE BLVD., N.W.					11/	11/30/2004										Sr.	VP Sales	& Mar	keting	
(Street) BOCA R	ATON FL		33487		_ 4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									ne) <mark>X</mark> F F	,				
(City)	(St	ate) (2	Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/Year)		ur) E	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)				es Acquired (A) or Of (D) (Instr. 3, 4 a		nd Securi		es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(1	A) or D)	Price		ansaction(s) istr. 3 and 4)				
Common Stock)/2004				J ⁽¹⁾	V	79.268	33	A	\$12	2.3	2,889.9355		D		
Common Stock																245 ⁽²⁾		I		By spouse
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Security or Exercise (Month/Day/Year) if any				n Date, Transaction Code (Inst				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)			8. Price Derivati Security (Instr. 5	tive ty 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Own Forn Direc or In (I) (Ir	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amo or Num of Shar	ber						

Explanation of Responses:

- 1. Voluntarily reported acquisition under the issuer's 2000 Employee Stock Purchase Plan, which is an exempt transaction pursuant to Rule 16b-3(c).
- 2. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Remarks:

/s/ James E. Dawson, as attorney-in-fact

Date

12/20/2004

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.